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Abstract: The local renin-angiotensin system (RAS) in the placenta plays a very important role in 
placental development. It is well known that during normal pregnancy most of the circulating and 
local RAS components are over-expressed and any disruption of this new balance may cause preg-
nancy complications. The aim of this study was to assess the metabolism of Ang I in placentas from 
normal pregnancy, in an ex vivo model, using an LC/MS method. The obtained results suggest that 
placental tissue is able to produce many angiotensin peptides but the main metabolite is Ang-(1–7).
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INTRODUCTION
The renin-angiotensin system (RAS) (the main pathways of the production of dif-
ferent angiotensins are presented in Fig. 1) plays a significant role in regulating 
arterial blood pressure and the water-electrolyte balance. During pregnancy, a num-
ber of RAS components are overexpressed, both in the blood and in tissues [1]. 
Due to the increase in extrarenal renin production, its plasma levels rise, and 
the increase in the concentration of circulating oestrogens results in higher pro-
duction of angiotensinogen in the liver. Angiotensin II (Ang II) also reaches high-
er plasma concentrations, though the angiotensin-converting enzyme (ACE) is 
a RAS component whose plasma level decreases in pregnancy [2, 3]. The presence 
of an active, local RAS in many tissues, including the placenta, has been proven. 
The placental RAS can be involved both physiologically and pathophysiologically 
in the processes occurring during pregnancy. It is well-known that Ang II takes 
part in the regulation of vascular resistance and blood flow in pregnancy — low 
concentrations of Ang II increase uteroplacental blood flow and high concentra-
tions decrease it [4]. In the mother’s cardiovascular system, in normal pregnan-
cy, the ability to generate angiotensin peptides rises, but blood vessels become 
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less sensitive to Ang II, which results in resistance to its pressor activity. To 
obtain the same vasomotor response as in non-pregnant women, pregnant ones 
require intravenous doses of Ang II that are twice as high [1, 5].
In studies carried out over the last decade, there were suggestions that a re-
cently described heptapeptide — angiotensin-(1–7) (Ang-(1–7)) — may play an 
important role in the regulation of arterial blood pressure during pregnancy [6–9]. 
Ang-(1–7) acts as an antagonist of Ang II — it exhibits vasodilating properties by 
releasing NO, kinins and prostacyclin. Contrary to Ang II, Ang-(1–7) decreases 
arterial blood pressure and inhibits angiogenesis. It has been shown that serum 
concentrations of Ang-(1–7) in patients in normal pregnancy reach much higher 
levels in comparison with pregnant women with pre-eclampsia. It is probable that 
changes in Ang-(1–7) levels, and particularly in the Ang-(1–7)/Ang II ratio, play 
a significant role in the pathogenesis of pre-eclampsia [8]. 
The studies conducted so far have shown the presence of individual RAS com-
ponents in the placenta — angiotensinogen, Ang I and Ang II as well as enzymes 
degrading each peptide and Ang II receptors. The studies were conducted on tis-
sues originating from human placentas, cell cultures and animal models, using 
immunoenzymatic, biochemical and molecular methods. There is little information 
Fig. 1. The main pathways of Angiotensin I metabolism (APA — aminopeptidase A;  
APN — aminopaptidase N; NEP — neutral endopeptidase; ACE — angiotensin converting enzyme; 
ACE2 — angiotensin converting enzyme type 2).
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about the production of Ang I metabolites other than Ang II and Ang-(1–7), which 
can also exhibit biological activity. 
The aim of this study was to examine the metabolism of angiotensin I, as 
a precursor of other angiotensins, in sections of placentas originating from normal 
pregnancies. In the study, we used an ex vivo model of angiotensin peptide gen-
eration, supplemented by the measurement of concentrations of each angiotensin 
using the high performance liquid chromatography mass spectrometry (LC/MS) 
method [10, 11].
MATERIAL AND METHODS
The study was carried out at the Department of Obstetrics and Perinatology and 
the Chair of Pharmacology of Collegium Medicum at the Jagiellonian Universi-
ty. In the study, we used sections of placentas coming from patients (n = 5) in 
normal pregnancy, without any concomitant chronic diseases or abnormalities 
found in the foetus, scheduled for elective caesarean sections (abnormal foetal 
presentation, foetopelvic disproportion). Tissues for examination were collected 
immediately after the caesarean sections (1 × 1 cm placental specimens from the 
area of the umbilical cord), washed with a refrigerated 0.9% NaCl solution, closed 
in a sterile container with refrigerated 0.9% NaCl and transported to the Chair 
of Pharmacology, where assays were performed. The time between the collection 
and the delivery of the material did not exceed 40 minutes in any of the cases. 
The research procedures were covered by the consent of the Bioethics Committee 
No. KBET/345/B/2012. 
TISSUE INCUBATION
The delivered sections of placentas were washed with normal saline at room 
temperature, then cleaned off any remaining thrombus and divided into smaller 
pieces. The cleaned sections of placentas were incubated in Krebs-Henseleit buf-
fer at the temperature of 37oC for 15 minutes in the presence of Ang I (the final 
concentration: 3 μM). The incubation of control samples was carried out with the 
same method (only buffer or buffer with Ang I, without tissue).
After incubation, the supernatant was secured for LC/MS analyses, while 
tissue sections were dried at the temperature of 60oC and weighed. 
PREPARATION OF SAMPLES FOR LC/MS ANALYSES
The supernatants from the incubation were purified and concentrated using Ul-
tra-Micro Spin C-18 columns (Harvard Apparatus, USA). The columns were con-
ditioned (300 μl of 0.1% TFA in 80% acetonitrile, 300 μl of 0.1% TFA) before 
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placing samples in them. 200 μl of each sample was acidified with formic acid to 
obtain pH <3, and then placed in the column and centrifuged (2 min, 1000 × g). 
Subsequently, the columns were washed with 300 μl of 0.1% TFA and angioten-
sin peptides were eluated with 300 μl of 0.1% TFA in 40% acetonitrile (2 min., 
1000 × g). The eluates were lyophilised overnight; then their dry remains were 
treated with 50 μl of 0.1% formic acid and subjected to LC/MS analysis. Samples 
for calibration curves, containing mixtures of standards of the assayed angioten-
sins, and control samples were prepared in the same way.
ANALYSIS OF THE PRODUCTS OF ANG I METABOLISM  
USING THE LC/MS METHOD
The chromatographic separation of angiotensin peptides was carried out with 
the use of a HPLC reversed-phase system (Ultimate 3000, Dionex USA), in an 
Acclaim PepMap 100 column (LC Packings, CA, USA), RP C18 (150 mm × 300 um 
ID, 5 μm particle size). 
The gradient flow of mobile phases was used: A — 4 mM ammonium formate 
buffer with 4 mM formic acid in 5% acetonitrile; B — 4 mM ammonium formate 
buffer with 4 mM formic acid in 95% acetonitrile. The flow rate of the mobile 
phases was 5 ml/min.
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Fig. 2. TIC chromatogram of angiotensins peptides standards. The insert presents extracted ions 
with masses corresponding to each peptide.
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The detection of the examined substances was carried out using an LCQ mass 
spectrometer (Finnigan Mat, San Jose, USA) with an ESI ion source (liquid-junc-
tion). The working parameters of the ESI-MS were as follows: electrospray needle 
voltage 2.5 kV; capillary voltage –5V; capillary temperature 200oC, positive ion 
mode. The SIM (selected ion monitoring) option was used in ion acquisition, es-
tablished during previous studies [10–13]. The obtained data was analysed with 
Xcalibur v.2.0 software. The separation of the standards of individual angiotensins 
is presented in Fig. 2. 
The concentrations of each angiotensin peptide were determined on the basis 
of calibration curves, determined using linear regression of the area under the 
peak in the peptide concentration function. The obtained values were converted 
to mg of dry tissue.
REAGENTS
The following reference substances and reagents were used during the experi-
ments: angiotensin peptide standards: Ang I, II, III, IV, 1–9, 1–7 and 1–5 were 
produced by Bachem, Switzerland; ammonium acetate, trifluoroacetic acid (TFA) 
and formic acid were manufactured by Fluka, Switzerland; acetonitrile was man-
ufactured by Merck, USA. 
The solutions of the reference substances, buffers and mobile phases for chro-
matographic separation were prepared with water obtained from a Simplicity 
Milliopore system (Merck Millipore, USA).
STATISTICAL ANALYSIS
The results are presented as mean values ± standard deviation. The significance 
of differences between the groups was tested with the use of one-way analysis 
of variance (ANOVA) as well as Scheffé’s post hoc test. A value of p <0.05 was 
accepted as statistically significant.
RESULTS
The sections of placentas exhibited an ability to convert Ang I to other metab-
olites. In the analysed samples, the presence of all the assayed metabolites of 
angiotensin I was shown (Fig. 3). Ex vivo, the main product of Ang I degradation 
turned out to be angiotensin-(1–7). Its production was 57.27 ± 9.14 ng/mg. The 
next two main Ang I metabolites were Ang II (5.31 ± 1.74 ng/mg) and Ang-(1–5) 
(3.97 ± 0.51 ng/mg). The remaining assayed metabolites — Ang-(19), Ang III and 
Ang IV — were produced in much lower quantities (<1 ng/mg).
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Fig. 3. The levels of angiotensins peptides produced during incubation of placenta sections  
in the presence of Ang I.
DISCUSSION
In this study, we showed that placental tissues coming from normal pregnancy are 
capable of degrading (converting) angiotensin I. The resulting Ang I degradation 
products require the presence of a number of enzymes, e.g. ACE, ACE2, NEP, 
chymases or aminopeptidases. During our study, we found that Ang-(1–7) is the 
main metabolite in placental tissues in normal pregnancy, which is consistent 
with other reports, which also showed the dominant production of Ang-(1–7) not 
only in the tissue RAS, but also in the plasma RAS [1, 9, 14]. 
In the classic approach, the renin-angiotensin system (RAS) is an endocrine 
system, in which the main, biologically active octapeptide — angiotensin II — is 
produced in plasma, as a result of the activity of angiotensin convertase (ACE), 
from a decapeptide, angiotensin I, separated from angiotensinogen (produced by 
the liver) by renin, released, in turn, by the ischaemic kidneys [15] (Fig. 1). In 
this approach, the biological effects of RAS stimulation depend mostly on the 
systemic activity of Ang II. In recent years, this traditional view of the RAS has 
changed considerably. It turned out that Ang I and Ang II can be converted by 
peptidases other than ACE (e.g. neutral endopeptidase — NEP — or the recently 
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discovered ACE2 isoform), promoting the occurrence of “non-typical” products 
[e.g. angiotensin-(1–7) or angiotensin-(1–9)], which often have specific receptors 
and perform important biological functions. Also, the presence of most RAS com-
ponents in a number of tissues (the tissue RAS) has been found and attention 
has been drawn to the important, paracrine activity of different angiotensins 
(often those “non-typical” ones), occurring locally, within individual organs. The 
most research has been devoted to the activity of the “local” RAS in the kidneys, 
heart, brain and the reproductive system. As it turns out, in all these areas, sig-
nificant functions of organs are regulated by the activity of different angiotensins 
balancing each other; their concentrations are determined by the tissue-specific 
activity profiles of each converting enzyme. The balance between Ang II and Ang-
(1–7) is the clearest [16, 17].
The research into the RAS in the physiology and pathophysiology of pregnancy 
conducted so far focuses mostly on the role of Ang II and Ang-(1–7). It has been 
shown that the expression of most RAS components changes as pregnancy pro-
gresses, both in the circulation and tissues. It is caused by hormonal changes 
occurring in the body of a woman during pregnancy. Oestrogens in uncompli-
cated pregnancy cause a shift in the production of angiotensin — the generation 
of Ang- (1–7) is increased and Ang II is reduced [18]. The observed decreased 
sensitivity to Ang II in normal pregnancies may be associated with the different 
structure of the type 1 angiotensin receptor (AT1), occurring then in the form of 
a monomer, in contrast with abnormal pregnancies, in which sensitivity to the 
activity of Ang II occurs, and the AT1 receptor has a heterodimeric structure 
[14, 19]. A disruption of the local RAS balance can result in the development of 
pregnancy complications, such as pre-eclampsia. In pregnancies complicated by 
pre-eclampsia, a lower expression of RAS components has been observed: lower 
concentrations of renin, Ang I and Ang II in comparison with normal pregnan-
cies [20]. In addition, it has been shown that, in patients with pre-eclampsia, 
the sensitivity to Ang II is increased, which manifests itself as increased pressor 
response to the activity of Ang II [1, 14].
In recent years, researchers have been stressing the important role of Ang-
(1–7) in the normal functioning of the placenta [8, 14]. In a study of plasma 
concentrations of Ang I, Ang II and Ang-(1–7) in pregnant patients (normal and 
complicated pregnancies) and non-pregnant ones, comparing Ang-(1–7)/Ang II, 
Ang-(1–7)/Ang I and Ang II/Ang I concentration ratios, a significant decrease in 
the value of all ratios in the non-pregnant women vs. women in normal pregnan-
cies group has been shown, while the non-pregnant vs. pregnant with pre-eclamp-
sia group only the Ang-(1–7)/Ang II ratio was significantly reduced (that is, there 
was a decrease in Ang-(1–7)). A negative correlation between the level of Ang-(1–7) 
and arterial blood pressure during pregnancy has been proven as well [8].
In this study, we showed that the main product of Ang I degradation in pla-
cental tissue originating from a normal pregnancy is Ang-(1–7). The placenta also 
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exhibits the ability to form other examined metabolites of Ang I, though they are 
produced in much smaller amounts. The ex vivo model used in the presented 
study and the LC/MS method, successfully used previously in research into Ang 
I, Ang-(1–12) and angiotensinogen conversions in different tissues (the aorta, 
heart, kidneys, adipose tissue) [10–13], allowed a comprehensive evaluation of 
angiotensin I conversion in placental tissues. Further research, extended to cover 
tissues coming from placentas from complicated pregnancies, using the presented 
method, may allow us to estimate changes in the production of each metabolite 
in different pathological states in the course of pregnancy, and thus shed new 
light on the impact of disruption in the placental metabolism of angiotensins on 
the development of these abnormalities. 
SUMMARY
The aim of this study was to investigate the metabolism of angiotensin I as 
a precursor of other angiotensins, in sections of placentas originating from nor-
mal pregnancies. An ex vivo model of angiotensins peptides generation developed 
earlier was applied. The measurement of individual angiotensin concentrations 
was performed with the high-performance liquid chromatography coupled with 
mass spectrometry (LC/MS) method. We proved that the main product of Ang 
I metabolism in placental tissue derived from physiological pregnancy is Ang-
(1–7). The placenta also exhibits the ability to generate other Ang I metabolites, 
although they are produced in much smaller quantities. The ex vivo model al-
lowed a comprehensive assessment of angiotensin I changes in healthy placental 
tissues. Further studies, extended to cover tissues from complicated pregnancies, 
may allow us to evaluate any changes in the production of various metabolites 
during pathological conditions in pregnancy, and thus shed light on some prob-
lems associated with the placental metabolism of angiotensins in the development 
of these abnormalities.
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